Gesche Wieser1, Ilinca Popp2, H Christian Rischke1,2, Vanessa Drendel3, Anca-Ligia Grosu2, Mark Bartholomä1, Wolfgang A Weber4, Rosalba Mansi5, Ulrich Wetterauer6, Wolfgang Schultze-Seemann6, Philipp T Meyer1,7, Cordula Annette Jilg8. 1. Department of Nuclear Medicine, Medical Center -Faculty of Medicine, University of Freiburg, Freiburg, Germany. 2. Department of Radiation Oncology, Medical Center - Faculty of Medicine, University of Freiburg, Freiburg, Germany. 3. Institute for Pathology, Faculty of Medicine, University of Freiburg, Freiburg, Germany. 4. Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5. Division of Radiological Chemistry, University Hospital Basel, Basel, Switzerland. 6. Department of Urology, Medical Center -Faculty of Medicine, University of Freiburg, Hugstetter Straße 55, 79102, Freiburg, Germany. 7. German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany. 8. Department of Urology, Medical Center -Faculty of Medicine, University of Freiburg, Hugstetter Straße 55, 79102, Freiburg, Germany. cordula.jilg@uniklinik-freiburg.de.
Abstract
PURPOSE/ BACKGROUND: [18F]fluoroethylcholine (18FECH) has been shown to be a valuable PET-tracer in recurrent prostate cancer (PCa), but still has limited accuracy. RM2 is a gastrin-releasing peptide receptor (GRPr) antagonist that binds to GRPr on PCa cells. Recent studies suggest that GRPr imaging with PET/CT is a promising technique for staging and restaging of PCa. We explore the value of GRPr-PET using the 68Ga-labeled GRPr antagonist RM2 in a selected population of patients with biochemically recurrent PCa and a negative/inconclusive 18FECH-PET/CT. MATERIAL AND METHODS: In this retrospective study 16 men with biochemical PCa relapse and negative (n = 14) or inconclusive (n = 2) 18FECH-PET/CT underwent whole-body 68Ga-RM2-PET/CT. Mean time from 18FECH-PET/CT to 68Ga-RM2-PET/CT was 6.1 ± 6.8 months. Primary therapies in these patients were radical prostatectomy (n = 13; 81.3%) or radiotherapy (n = 3; 18.7%). 14/16 patients (87.5%) had already undergone salvage therapies because of biochemical relapse prior to 68Ga-RM2-PET/CT imaging. Mean ± SD PSA at 68Ga-RM2-PET/CT was 19.4 ± 53.5 ng/ml (range 1.06-226.4 ng/ml). RESULTS: 68Ga-RM2-PET/CT showed at least one region with focal pathological uptake in 10/16 patients (62.5%), being suggestive of local relapse (n = 4), lymph node metastases (LNM; n = 4), bone metastases (n = 1) and lung metastasis with hilar LNM (n = 1). Seven of ten positive 68Ga-RM2 scans were positively confirmed by surgical resection and histology of the lesions (n = 2), by response to site-directed therapies (n = 2) or by further imaging (n = 3). Patients with a positive 68Ga-RM2-scan showed a significantly higher median PSA (6.8 ng/ml, IQR 10.2 ng/ml) value than those with a negative scan (1.5 ng/ml, IQR 3.1 ng/ml; p = 0.016). Gleason scores or concomitant antihormonal therapy had no apparent impact on the detection of recurrent disease. CONCLUSION: Even in this highly selected population of patients with known biochemical recurrence but negative or inconclusive 18FECH-PET/CT, a 68Ga-RM2-PET/CT was helpful to localize PCa recurrence in the majority of the cases. Thus, 68Ga-RM2-PET/CT deserves further investigation as a promising imaging modality for imaging PCa recurrence.
PURPOSE/ BACKGROUND:[18F]fluoroethylcholine (18FECH) has been shown to be a valuable PET-tracer in recurrent prostate cancer (PCa), but still has limited accuracy. RM2 is a gastrin-releasing peptide receptor (GRPr) antagonist that binds to GRPr on PCa cells. Recent studies suggest that GRPr imaging with PET/CT is a promising technique for staging and restaging of PCa. We explore the value of GRPr-PET using the 68Ga-labeled GRPr antagonist RM2 in a selected population of patients with biochemically recurrent PCa and a negative/inconclusive 18FECH-PET/CT. MATERIAL AND METHODS: In this retrospective study 16 men with biochemical PCa relapse and negative (n = 14) or inconclusive (n = 2) 18FECH-PET/CT underwent whole-body 68Ga-RM2-PET/CT. Mean time from 18FECH-PET/CT to 68Ga-RM2-PET/CT was 6.1 ± 6.8 months. Primary therapies in these patients were radical prostatectomy (n = 13; 81.3%) or radiotherapy (n = 3; 18.7%). 14/16 patients (87.5%) had already undergone salvage therapies because of biochemical relapse prior to 68Ga-RM2-PET/CT imaging. Mean ± SD PSA at 68Ga-RM2-PET/CT was 19.4 ± 53.5 ng/ml (range 1.06-226.4 ng/ml). RESULTS: 68Ga-RM2-PET/CT showed at least one region with focal pathological uptake in 10/16 patients (62.5%), being suggestive of local relapse (n = 4), lymph node metastases (LNM; n = 4), bone metastases (n = 1) and lung metastasis with hilar LNM (n = 1). Seven of ten positive 68Ga-RM2 scans were positively confirmed by surgical resection and histology of the lesions (n = 2), by response to site-directed therapies (n = 2) or by further imaging (n = 3). Patients with a positive 68Ga-RM2-scan showed a significantly higher median PSA (6.8 ng/ml, IQR 10.2 ng/ml) value than those with a negative scan (1.5 ng/ml, IQR 3.1 ng/ml; p = 0.016). Gleason scores or concomitant antihormonal therapy had no apparent impact on the detection of recurrent disease. CONCLUSION: Even in this highly selected population of patients with known biochemical recurrence but negative or inconclusive 18FECH-PET/CT, a 68Ga-RM2-PET/CT was helpful to localize PCa recurrence in the majority of the cases. Thus, 68Ga-RM2-PET/CT deserves further investigation as a promising imaging modality for imaging PCa recurrence.
Authors: Bert-Ram Sah; Irene A Burger; Roger Schibli; Matthias Friebe; Ludger Dinkelborg; Keith Graham; Sandra Borkowski; Claudia Bacher-Stier; Ray Valencia; Ananth Srinivasan; Thomas F Hany; Linjing Mu; Peter J Wild; Niklaus G Schaefer Journal: J Nucl Med Date: 2015-02-12 Impact factor: 10.057
Authors: David Pfister; Daniel Porres; Axel Heidenreich; Isabel Heidegger; Ruth Knuechel; Florian Steib; Florian F Behrendt; Frederik A Verburg Journal: Eur J Nucl Med Mol Imaging Date: 2016-03-19 Impact factor: 9.236
Authors: Misop Han; Alan W Partin; Marianna Zahurak; Steven Piantadosi; Johnathan I Epstein; Patrick C Walsh Journal: J Urol Date: 2003-02 Impact factor: 7.450
Authors: Esa Kähkönen; Ivan Jambor; Jukka Kemppainen; Kaisa Lehtiö; Tove J Grönroos; Anna Kuisma; Pauliina Luoto; Henri J Sipilä; Tuula Tolvanen; Kalle Alanen; Jonna Silén; Markku Kallajoki; Anne Roivainen; Niklaus Schäfer; Roger Schibli; Martina Dragic; Anass Johayem; Ray Valencia; Sandra Borkowski; Heikki Minn Journal: Clin Cancer Res Date: 2013-08-09 Impact factor: 12.531
Authors: Gesche Wieser; Rosalba Mansi; Anca L Grosu; Wolfgang Schultze-Seemann; Rebecca A Dumont-Walter; Philipp T Meyer; Helmut R Maecke; Jean Claude Reubi; Wolfgang A Weber Journal: Theranostics Date: 2014-02-01 Impact factor: 11.556
Authors: Ingrid J G Burvenich; Sagun Parakh; Adam C Parslow; Sze Ting Lee; Hui K Gan; Andrew M Scott Journal: AAPS J Date: 2018-03-08 Impact factor: 4.009
Authors: Paola Mapelli; Samuele Ghezzo; Ana Maria Samanes Gajate; Erik Preza; Anna Palmisano; Vito Cucchiara; Giorgio Brembilla; Carolina Bezzi; Riccardo Rigamonti; Patrizia Magnani; Elisa Toninelli; Valentino Bettinardi; Nazareno Suardi; Luigi Gianolli; Paola Scifo; Alberto Briganti; Francesco De Cobelli; Antonio Esposito; Maria Picchio Journal: Cancers (Basel) Date: 2022-01-11 Impact factor: 6.639